Advertisement

Study to Evaluate Imatinib in Desmoid Tumors

13:19 EDT 18th May 2013 | BioPortfolio

Summary

The objective of the present study is to evaluate the activity and safety of imatinib in patients with aggressive fibromatosis who, after receiving the standard therapy, show an inoperable recurrent tumor or disease not readily controllable by surgery or radiotherapy.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Aggressive Fibromatosis

Intervention

Imatinib

Location

University of Heidelberg, Mannheim University Medical Center
Mannheim
Germany
68167

Status

Recruiting

Source

University of Heidelberg

Results (where available)

View Results

Links

Medical and Biotech [MESH] Definitions

Fibromatosis, Aggressive

A childhood counterpart of abdominal or extra-abdominal desmoid tumors, characterized by firm subcutaneous nodules that grow rapidly in any part of the body but do not metastasize. The adult form of abdominal fibromatosis is FIBROMATOSIS, ABDOMINAL. (Stedman, 25th ed)

Dupuytren Contracture

A fibromatosis of the palmar fascia characterized by thickening and contracture of the fibrous bands on the palmar surfaces of the hand and fingers. It arises most commonly in men between the ages of 30 and 50.

Fibromatosis, Abdominal

A relatively large mass of unusually firm scarlike connective tissue resulting from active participation of fibroblasts, occurring most frequently in the abdominal muscles of women who have borne children. The fibroblasts infiltrate surrounding muscle and fascia. (Stedman, 25th ed)

Adamantinoma

A locally aggressive, osteolytic neoplasm of the long bones, probably of epithelial origin and most often involving the TIBIA.

Violence

Individual or group aggressive behavior which is socially non-acceptable, turbulent, and often destructive. It is precipitated by frustrations, hostility, prejudices, etc.

Clinical Trials [ 283 Associated Clinical Trials listed on BioPortfolio]

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects of imat...

Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib

In order to distinguish between clonal instability driven by imatinib in CML and actual changes with secondary clones induced by imatinib we would like to investigate the karyotype of non-...

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy....

STI571 ProspectIve RandomIzed Trial: SPIRIT

To test whether increasing the dose of imatinib or combining it with IFNalpha or ara-C increases the rate of molecular response (as measured by the decrease in BCR-ABL transcripts after 12...

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Anaplastic thyroid cancers are rare, aggressive tumors. Standard treatment options include surgery and chemoradiation. Few treatment options are available once metastases develop. Recent d...

PubMed Articles [ 2077 Associated PubMed Articles listed on BioPortfolio]

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.

Background:Imatinib induces responses and disease stabilisations in non-resectable patients with aggressive fibromatosis (AF). The precise target of imatinib in AF and predictive factors for response...

Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.

PURPOSE: Aggressive fibromatoses (AF, desmoid tumors) are rare clonal neoplastic proliferations of connective tissues that can be locally aggressive despite wide surgical resection and/or radiation th...

Aggressive Fibromatosis (Desmoid Tumor) Is Derived from Mesenchymal Progenitor Cells.

The cellular origins from which most tumors arise are poorly defined, especially in mesenchymal neoplasms. Aggressive fibromatosis, also known as desmoid tumor, is a locally invasive soft tissue tumor...

Huge retrovesical tumor as an incidental finding : Desmoid-type fibromatosis: a case report.

We report the case of a 57-year-old patient with a huge, retrovesical, aggressive desmoid fibromatosis detected incidentally during preoperative staging for radical prostatectomy. The tumor was locall...

Correction: aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells.

More From BioPortfolio on "Study to Evaluate Imatinib in Desmoid Tumors"

Search BioPortfolio: